Serum from Men with the Severe Form of COVID-19 Impairs the Nitric Oxide Signaling Pathway in Isolated Corpus Cavernosum from Mice: An In Vitro Study

Table 1

Characteristics of patients from the control and COVID-19 groups.

	Control ()	COVID-19 ()	value
Age (years; )			0.3
Classes of medication in use
Hormone	10%	14.3%	0.8
Angiotensin-converting enzyme inhibitors	10%	28.6%	0.3
Angiotensin II receptor antagonists	30%	14.3%	0.6
Antihyperglycemic agents	0	14.3%	0.2
Diuretics	0	14.3%	0.2
Statins	0	14.3%	0.2
Anticoagulants	0	14.3%	0.2
Antiplatelets	0	14.3%	0.2
Antiemetics	0	14.3%	0.2
Comorbidities
Hypertension	40%	57.1%	0.2
Overweight (BMI 25-29.9 kg/m^2)	10%	0%	0.2
Obesity ( kg/m^2)	10%	28.6%	0.3
Diabetes	0	28.6%	0.03
Clinical characteristics
Hospitalization (days, )	0	23.6 ± 6.6	0.0005
ICU hospitalization (days, )	0		0.001
Mortality rate (%)	0	42.9	0.01
Laboratory tests
Creatinine (mg/dL, )			0.09
Lymphocytes (mm^3, )			0.008
Platelets (×10^3/L, )			0.02
C-reactive protein (mg/dL, )			0.007
IL-6 serum levels (pg/mL, )			0.006
TNF-α serum levels (pg/mL, )			0.01

BMI: body mass index; ICU: intensive care unit; , control vs. COVID-19, unpaired -test. SEM: standard error of the mean.